379229-83-1

Basic information

• Product Name: 5-CHLORO-1,3-BENZODIOXOLE-4-CARBOXYLIC ACID
• Synonyms: 5-CHLORO-BENZO[1,3]DIOXOLE-4-CARBOXYLIC ACID;5-CHLORO-1,3-BENZODIOXOLE-4-CARBOXYLIC ACID;5-chlorobenzo[d][1,3]dioxole-4-carboxylic acid;1,3-Benzodioxole-4-carboxylic acid, 5-chloro-;5-chlorobenzo[d][1,3]dioxole
• CAS NO: 379229-83-1
• Molecular Formula: C₈H₅ClO₄
• Molecular Weight: 200.58
• Mol File: 379229-83-1.mol

Chemical Properties

• Boiling Point: 342.3 °C at 760 mmHg
• Flash Point: 160.8 °C
• Appearance: /
• Density: 1.603
• Vapor Pressure: 2.92E-05mmHg at 25°C
• Refractive Index: 1.625
• CAS DataBase Reference: 5-CHLORO-1,3-BENZODIOXOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-1,3-BENZODIOXOLE-4-CARBOXYLIC ACID(379229-83-1)
• EPA Substance Registry System: 5-CHLORO-1,3-BENZODIOXOLE-4-CARBOXYLIC ACID(379229-83-1)

Safety Data

• Hazardous Substances Data: 379229-83-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-Chloro-1,3-benzodioxole-4-carboxylic acid is utilized as an intermediate in the synthesis of pharmaceuticals and agrochemicals, playing a crucial role in the development of new drugs and agricultural products.
Used in Chemical Process Development:
5-Chloro-1,3-benzodioxole-4-carboxylic acid is employed in the development of chemical processes, where its unique properties can contribute to the creation of innovative and efficient methods in the chemical industry.
Used as a Reagent in Organic Synthesis:
5-Chloro-1,3-benzodioxole-4-carboxylic acid serves as a reagent in organic synthesis, facilitating various chemical reactions that are essential for the production of complex organic compounds.
Used in Medicinal Chemistry and Drug Discovery:
Due to its structural features, 5-Chloro-1,3-benzodioxole-4-carboxylic acid may have potential applications in the field of medicinal chemistry and drug discovery, where it could be instrumental in the design and synthesis of novel therapeutic agents.

InChI:InChI=1/C8H5ClO4/c9-4-1-2-5-7(13-3-12-5)6(4)8(10)11/h1-2H,3H2,(H,10,11)

Upstream product

• 7228-38-8 5-chloro-1,3-benzodioxole 
• 124-38-9 carbon dioxide 

Downstream Products

• 379228-45-2 5-chlorobenzo[d][1,3]dioxolcyclopenten-4-amine 
• 379229-84-2 tert-butyl (5-chloro-1,3-benzodioxol-4-yl)carbamate 

Relevant articles and documents

Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive phenotype. We report here the discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of the c-Src enzyme. Special attention was directed toward finding inhibitors selective against KDR tyrosine kinase in order to ensure that the in vivo profile of a specific Src inhibitor could be determined. The 4-aminobenzodioxole quinazoline series gave compounds with excellent potency and selectivity. The most interesting compounds were evaluated in vivo and displayed good pharmacokinetics following oral dosing. Compounds such as the aminobenzodioxoles were shown to be potent inhibitors of tumor growth in a c-Src-transformed 3T3 xenograft model in vivo, resulting in more than 90% growth inhibition at doses as low as 6 mg/kg po once daily. Src tyrosine kinase inhibitors such as these may provide a novel therapeutic modality for targeting cancer invasion and metastasis.

QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER

The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3,Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS

The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.